5-amino-1MQ for fat loss: what the caption gets right and wrong

What did @shesfuntho2 actually say?

The creator describes 5-amino-1MQ (5A1MQ) as a small molecule that inhibits an enzyme responsible for degrading NAD, framing it as a "recycle and reuse" approach rather than pushing more NAD into the system. They claim it targets white adipose tissue, has been studied in cancer and longevity contexts in mice, and mention it could be paired with a GLP-1 receptor agonist for weight loss. They also say it produces "virtually no side effects" based on one study they encountered.

To the creator's credit, they frame this explicitly as personal research, not medical advice. They mention their own negative experience with an oral form and position the video as informational. That kind of hedging matters, but 41,000 views means the claims travel far regardless of the disclaimer.

Does the science back this up?

Partially, yes. The mechanism is real. 5-amino-1MQ is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that consumes SAM (S-adenosylmethionine) and indirectly depletes NAD+ pools. Blocking NNMT does appear to support NAD+ availability rather than flooding the system with precursors like NMN or NR. That distinction is legitimate and often overlooked in popular NAD discussions.

The white adipose tissue claim has some backing. Mehmel et al. (2020, Nutrients) and Brachs et al. (2019, Molecular Metabolism) both found NNMT inhibition associated with reduced fat accumulation in preclinical models, with some preservation of lean mass. The cancer research is real but almost entirely murine. The "virtually no side effects" phrase almost certainly comes from Gao et al. (2021, Nature Communications), where the compound showed a clean safety profile in mice. That does not translate directly to humans, and the creator does not make that distinction clearly enough.

What did they get wrong (or right)?

They got the core mechanism right. NNMT inhibition as a strategy to preserve NAD+ is a real and interesting area of research, and the "recycle rather than push" framing is a fair lay description of how it differs from NMN supplementation. Credit where it's due.

What they got wrong, or at least incomplete: citing "virtually no side effects" from a mouse study as if it applies to humans is a meaningful leap. There are no published Phase I or Phase II human trials on 5-amino-1MQ as of mid-2024. The compound is not FDA-approved, not available as a regulated pharmaceutical, and clinical safety data in humans is essentially nonexistent. The cancer research they reference is preclinical only. Mentioning it in the same breath as weight loss could give viewers the impression it is a proven cancer intervention, which it is not. The suggestion to stack it with a GLP-1 agonist is speculative and has no human trial support.

What should you actually know?

5-amino-1MQ is a research compound. That means it has not gone through the safety and efficacy testing required for human therapeutic use. The preclinical data on NNMT inhibition is genuinely interesting, and researchers like Canto et al. have built a solid mechanistic case for why NAD+ metabolism matters in metabolic disease and aging. But interesting preclinical data has a poor track record of translating cleanly to human outcomes.

If you are considering this compound through a telehealth or compounding channel, you should ask hard questions: what is the sourcing, what testing has been done on the batch, and what does your provider actually know about the human pharmacokinetics? The "no side effects" claim from one mouse study is not a safety certificate. The weight-loss and longevity framing is ahead of the evidence. And stacking unregulated peptides or small molecules with GLP-1 agonists without physician oversight introduces risks that no TikTok video can adequately capture.